EXEL or LQDA: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Liquidia Corporation (LQDA). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Feb 12, 2026

Liquidia Corporation (LQDA) is a Great Momentum Stock: Should You Buy?

Does Liquidia Corporation (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Jan 15, 2026

Liquidia Corporation (LQDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Liquidia Corporation (LQDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 15, 2026

Why Liquidia Stock Rocked the Market Today

The biotech posted preliminary sales results for Yutrepia. This is its latest commercialized product, approved by the FDA in May 2025.

The Motley Fool • Jan 9, 2026

Liquidia: Yutrepia's Attributes In Focus, But Binary Risk Shouldn't Be Ignored

Liquidia Corporation remains a Buy for risk-tolerant biotech investors, supported by strong Yutrepia launch metrics and product differentiation in PAH and PH-ILD. LQDA's Yutrepia demonstrates superior tolerability, higher achievable dosing, and rapid titration versus Tyvaso, driving robust commercial uptake and market share gains. Key binary risk centers on the imminent IP litigation outcome versus United Therapeutics; multiple scenarios could impact valuation, but commercial momentum is strong.

Seeking Alpha • Jan 8, 2026

HRMY vs. LQDA: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Liquidia Corporation (LQDA). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • Jan 8, 2026

Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus

Liquidia shares have surged 43.9% since an October upgrade, as Zacks highlights stock wins and portfolio results despite a volatile market.

Zacks Investment Research • Dec 15, 2025

Wall Street Analysts See a 51.15% Upside in Liquidia Corporation (LQDA): Can the Stock Really Move This High?

The consensus price target hints at a 51.2% upside potential for Liquidia Corporation (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Nov 24, 2025

Liquidia Corporation (LQDA) Presents at Jefferies London Healthcare Conference 2025 Transcript

Liquidia Corporation ( LQDA ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:00 AM EST Company Participants Roger Jeffs - CEO & Director Michael Kaseta - COO & CFO Conference Call Participants Amy Li - Jefferies LLC, Research Division Presentation Amy Li Jefferies LLC, Research Division Hi, everyone, thanks so much for attending the Liquidia fireside chat. Day 2 of the conference, the weather in London is getting a little chilly, but it's good for staying awake.

Seeking Alpha • Nov 19, 2025

This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch

California-based TCG Crossover Management added 1.7 million shares of Liquidia for an estimated $38.9 million in the third quarter. The position represented 1.9% of reported assets at quarter-end.

The Motley Fool • Nov 17, 2025